Discovery of a promising agonist adjuvant
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
List view / Grid view
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
Certain sensory neurons and Substance P are potential drug targets for the development of novel allergy preventions or treatments, according to scientists.
A cancer drug for patients with certain types of leukaemia and lymphoma can also prevent reactions to some of the most common airborne allergens, according to a recent Northwestern Medicine study. The promising data from this pilot study could have greater implications for adults with food allergies.